v3.3.1.900
Selected Quarterly Financial Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Jan. 03, 2016
 [1]
Sep. 27, 2015
 [2]
Jun. 28, 2015
 [3]
Mar. 29, 2015
 [4]
Dec. 28, 2014
 [5]
Sep. 28, 2014
 [6]
Jun. 29, 2014
 [7]
Mar. 30, 2014
 [8]
Jan. 03, 2016
Dec. 28, 2014
Dec. 29, 2013
Summary of Selected Quarterly Financial Data (unaudited)                      
Sales to customers $ 17,811 $ 17,102 $ 17,787 $ 17,374 $ 18,254 $ 18,467 $ 19,495 $ 18,115 $ 70,074 $ 74,331 $ 71,312
Gross profit 12,138 11,878 12,430 12,092 12,401 13,068 13,456 12,660 48,538 51,585 48,970
Earnings before provision for taxes on income 3,758 4,122 5,741 5,575 2,703 6,810 5,626 5,424 19,196 [9] 20,563 [10] 15,471 [11]
Net earnings $ 3,215 $ 3,358 $ 4,516 $ 4,320 $ 2,521 $ 4,749 $ 4,326 $ 4,727 $ 15,409 $ 16,323 $ 13,831
Basic net earnings per share $ 1.16 $ 1.21 $ 1.63 $ 1.55 $ 0.90 $ 1.69 $ 1.53 $ 1.67 $ 5.56 $ 5.80 $ 4.92
Diluted net earnings per share $ 1.15 $ 1.20 $ 1.61 $ 1.53 $ 0.89 $ 1.66 $ 1.51 $ 1.64 $ 5.48 $ 5.70 $ 4.81
Consumer [Member]                      
Summary of Selected Quarterly Financial Data (unaudited)                      
Sales to customers $ 3,320 $ 3,314 $ 3,483 $ 3,390 $ 3,606 $ 3,589 $ 3,744 $ 3,557      
Pharmaceutical [Member]                      
Summary of Selected Quarterly Financial Data (unaudited)                      
Sales to customers 8,064 7,694 7,946 7,726 7,999 8,307 8,509 7,498      
Medical Devices [Member]                      
Summary of Selected Quarterly Financial Data (unaudited)                      
Sales to customers $ 6,427 $ 6,094 $ 6,358 $ 6,258 $ 6,649 $ 6,571 $ 7,242 $ 7,060      
[1] The fourth quarter of 2015 includes a restructuring charge of $415 million after-tax ($590 million before-tax), $156 million after-tax ($214 million before-tax) from impairment of in-process research and development and Synthes integration costs of $59 million after-tax ($83 million before-tax). Additionally, the fourth quarter of 2015 includes the gain on the Cordis divestiture.
[2] The third quarter of 2015 includes net litigation expense of $348 million after-tax ($409 million before-tax).
[3] The second quarter of 2015 includes net litigation expense of $23 million after-tax ($134 million before-tax).
[4] The first quarter of 2015 includes a net litigation gain of $253 million after-tax ($402 million before-tax) and $122 million after-tax ($139 million before-tax) for costs associated with the DePuy ASRTM Hip program.
[5] The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
[6] The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
[7] The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
[8] The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.
[9] The Medical Devices segment includes a restructuring charge of $590 million, an intangible asset write-down of $346 million related to Acclarent, Synthes integration costs of $196 million and $148 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $224 million of in-process research and development expense, comprised of $214 million and $10 million in the Pharmaceutical and Medical Devices segments, respectively. Includes net litigation expense of $141 million comprised of $136 million in the Pharmaceutical segment and $5 million in the Medical Devices segment, which included the gain from the litigation settlement agreement with Guidant for $600 million. The Medical Devices Segment includes a gain of $1.3 billion from the divestiture of the Cordis business. The Pharmaceutical segment includes a gain of $981 million from the U.S. divestiture of NUCYNTA® and a positive adjustment of $0.5 billion to previous reserve estimates, including Managed Medicaid rebates. The Consumer segment includes a gain of $229 million from the divestiture of SPLENDA® brand.
[10] Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. The Pharmaceutical segment includes an additional year of the Branded Prescription Drug Fee of $220 million and a positive adjustment of $0.1 billion to previous reserve estimates.
[11] Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.